Dendreon Shareholders Complain About Stock Losses By Sam | April 8, 2016 Dendreon shareholders strafed the Seattle biotechnology company’s leadership with criticism at Wednesday’s annual meeting, upset at the stock’s 82 percent decline in the past year. Posted in FDAnews Drug Daily Bulletin